Sanofi/Regeneron Dupixent; Alkermes' antipsychotic get dates with the FDA; Concert wins reprieve in Incyte patent fight
→ Sanofi and Regeneron’s biologic Dupixent, widely considered the best-in-class therapy for atopic dermatitis is now up for FDA approval in children aged 6 to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
